GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » Interest Coverage

Organovo Holdings (Organovo Holdings) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Organovo Holdings's Operating Income for the three months ended in Dec. 2023 was $-3.68 Mil. Organovo Holdings's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Organovo Holdings Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Organovo Holdings's Interest Coverage or its related term are showing as below:


ONVO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Organovo Holdings Interest Coverage Historical Data

The historical data trend for Organovo Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Organovo Holdings Interest Coverage Chart

Organovo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt N/A N/A

Organovo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Organovo Holdings's Interest Coverage

For the Biotechnology subindustry, Organovo Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Interest Coverage falls into.



Organovo Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Organovo Holdings's Interest Coverage for the fiscal year that ended in Mar. 2023 is calculated as

Here, for the fiscal year that ended in Mar. 2023, Organovo Holdings's Interest Expense was $0.00 Mil. Its Operating Income was $-17.73 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.31 Mil.

GuruFocus does not calculate Organovo Holdings's interest coverage with the available data.

Organovo Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Organovo Holdings's Interest Expense was $0.00 Mil. Its Operating Income was $-3.68 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.00 Mil.

GuruFocus does not calculate Organovo Holdings's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Organovo Holdings  (NAS:ONVO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Organovo Holdings Interest Coverage Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (Organovo Holdings) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075